Viatris MR-107A-02 New Drug Application Accepted by FDA
Viatris announced that the U.S. FDA has accepted for review the New Drug Application for MR-107A-02, a non-opioid, for the treatment of moderate-to-severe acute pain. The FDA has assigned a PDUFA goal date of Dec. 27, 2026.
